Literature DB >> 28141621

High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders.

Thierry Q Mentzel1, Ritsaert Lieverse, Oswald Bloemen, Wolfgang Viechtbauer, Peter N van Harten.   

Abstract

BACKGROUND: Drug-related movement disorders (DRMDs) reduce quality of life and contribute to medication noncompliance of patients with psychotic disorders. Little is known about the epidemiology of DRMDs in relatively young patients a few years after onset of psychosis. This is an important period to study, as the impact of the antipsychotic treatment on the long-term potentiation of the neural pathways associated with psychotic disorders and DRMDs is still minimal. This study investigated the prevalence, incidence, persistence, and clinical correlates of DRMDs in patients during their first years after disease onset.
METHODS: The Genetic Risk and Outcome of Psychosis study is a longitudinal study of 1120 relatively young patients with nonaffective psychosis and a mean age and illness duration of 27 and 4 years, respectively. The following drug-related movement disorders were assessed at baseline and at the 3-year follow-up: parkinsonism, akathisia, tardive dyskinesia, and tardive dystonia. We determined prevalence, incidence, and persistence and investigated clinical correlates at and over the baseline and follow-up assessment.
RESULTS: Patients' mean age and illness duration at baseline were 27.1 and 4.3 years, respectively. In 4 patients, 1 developed a DRMD over the 3-year study period. Prevalence, incidence, and persistence rates were highest for parkinsonism (32%, 21%, and 53%) followed by akathisia (9%, 5%, and 17%) and tardive dyskinesia (4%, 3%, and 20%). Significant associations were found between DRMDs and the patients' age, IQ, and psychopathology.
CONCLUSIONS: The prevalence, persistence, and incidence of DRMDs in this sample were high despite the relatively young age, recent onset of the disorder, and treatment primarily with second-generation antipsychotics. These findings emphasize that screening, diagnosis, and treatment of DRMDs are still important.

Entities:  

Mesh:

Year:  2017        PMID: 28141621     DOI: 10.1097/JCP.0000000000000666

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  11 in total

Review 1.  Motor System Pathology in Psychosis.

Authors:  Sebastian Walther; Vijay A Mittal
Journal:  Curr Psychiatry Rep       Date:  2017-10-30       Impact factor: 5.285

Review 2.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

3.  Motion energy analysis reveals altered body movement in youth at risk for psychosis.

Authors:  Derek J Dean; Alayna T Samson; Raeana Newberry; Vijay A Mittal
Journal:  Schizophr Res       Date:  2017-06-03       Impact factor: 4.939

4.  Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia.

Authors:  Jiajun Weng; Yan Zhang; Huafang Li; Yifeng Shen; Wenjuan Yu
Journal:  Gen Psychiatr       Date:  2019-02-23

Review 5.  The genetics of drug-related movement disorders, an umbrella review of meta-analyses.

Authors:  Nadine C van der Burg; Asmar F Y Al Hadithy; Peter N van Harten; Jim van Os; P Roberto Bakker
Journal:  Mol Psychiatry       Date:  2020-02-04       Impact factor: 15.992

6.  Asymmetric Drug-Induced Parkinsonism and Psychopathology: A Prospective Naturalistic Study in Long-Stay Psychiatric Patients.

Authors:  Lydia E Pieters; P Roberto Bakker; Peter N van Harten
Journal:  Front Psychiatry       Date:  2018-02-05       Impact factor: 4.157

7.  Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study.

Authors:  Yirgalem Shewakena Wubeshet; Oumer Sada Mohammed; Tigestu Alemu Desse
Journal:  BMC Psychiatry       Date:  2019-01-18       Impact factor: 3.630

8.  Hemiataxia: A Novel Presentation of Anti-NMDA Receptor Antibody Mediated Encephalitis in an Adolescent.

Authors:  Greg D Phillips; Gillian N Jones; Maureen Callaghan; Marc P DiFazio
Journal:  Case Rep Psychiatry       Date:  2017-12-03

9.  Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis.

Authors:  Bettina Balint; Helen Killaspy; Louise Marston; Thomas Barnes; Anna Latorre; Eileen Joyce; Caroline S Clarke; Rosa De Micco; Mark J Edwards; Roberto Erro; Thomas Foltynie; Rachael M Hunter; Fiona Nolan; Anette Schrag; Nick Freemantle; Yvonne Foreshaw; Nicholas Green; Kailash P Bhatia; Davide Martino
Journal:  BJPsych Open       Date:  2018-09-27

10.  Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study.

Authors:  Jia Jun Weng; Li Hua Wang; Hao Zhu; Wen Rong Xu; Yu Mei Wei; Zhi Yang Wang; Wen Juan Yu; Hua Fang Li
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.